Ramucirumab
Cyramza · Anti-VEGFR2 antibody
Hypertension and proteinuria, class effect.
HTNGLOMTMA
ModerateOpen →
VEGFR TKI
Axitinib
Inlyta · Axi
A potent, selective second-generation VEGFR inhibitor whose renal signature is dose-related hypertension and proteinuria, with thrombotic microangiopathy at the severe end of the spectrum.
ModerateVEGFR tyrosine kinase inhibitor · approved 2012
Advanced (metastatic) renal cell carcinoma after failure of one prior systemic therapy (second-line monotherapy)First-line advanced renal cell carcinoma in combination with an immune checkpoint inhibitor (e.g., pembrolizumab or avelumab)
Signature kidney injury
Hypertension
Representative incidence40.4%
Hypertension is the dominant and best-quantified renal-relevant signal. In the randomized phase III AXIS trial, treatment-emergent all-causality hypertension occurred in 40.4% of axitinib-treated patients (vs 29.0% with sorafenib), with grade 3 hypertension in 15.3% and grade 4 in 0.3%. A real-world VEGFR-TKI cohort in metastatic RCC similarly found hypertension to be the single most common anti-angiogenesis-related adverse event (about 48.6% in TKI-naive patients across the class). Proteinuria is the next most common renal effect; across the VEGF-inhibitor class mild/asymptomatic proteinuria is reported in roughly 21% to 63% of patients, with heavy (nephrotic-range) proteinuria in up to about 6.5% of RCC patients, and axitinib-specific proteinuria rates have been higher in some populations (e.g., Japanese cohorts). Thrombotic microangiopathy and other glomerular lesions (FSGS-like injury, podocytopathy, hyaline occlusive glomerular microangiopathy) are reported at the severe, biopsy-level end of the spectrum but are not precisely quantified for axitinib specifically.
Source: Rini, Target Oncol 2014 (AXIS hypertension analysis)
Toxicity fingerprint
Tap a signature to trace where it strikes the nephron.
0%incidence
SeverityModerate
ReversibilityPartially reversible
Evidence0 refs
Nephron map
GlomerulusFiltration barrier (podocytes + endothelium)
Vasculature / EndotheliumGlomerular & peritubular capillaries
Hypertension
On-target loss of endothelial nitric oxide from VEGF-pathway blockade — so characteristic it has been studied as a pharmacodynamic marker of drug exposure.
Mechanism of kidney injury
Most renal toxicity is on-target VEGF-pathway inhibition acting on the glomerulus and vasculature. VEGF is constitutively produced by podocytes and is essential for the health of the glomerular endothelium and the slit-diaphragm protein nephrin; blocking VEGFR signaling downregulates or suppresses nephrin and injures glomerular endothelial cells, producing proteinuria and, in severe cases, a glomerular thrombotic microangiopathy (endothelial swelling, fibrin thrombi, mesangiolysis). The same loss of endothelial VEGF tone reduces nitric oxide and prostacyclin and causes rarefaction of the microvasculature, raising systemic vascular resistance and driving hypertension. Other reported glomerular patterns (focal segmental glomerulosclerosis, minimal-change-like podocytopathy) are thought to reflect podocyte injury from VEGF deprivation. These are class effects shared across VEGF/VEGFR inhibitors.
Clinical presentation
New or worsening hypertension, often within the first weeks of therapy, is the most common presentation and may be marked. Proteinuria ranges from asymptomatic dipstick/quantitative proteinuria detected on monitoring to overt nephrotic-range proteinuria with edema. The severe phenotype is a thrombotic microangiopathy or nephrotic syndrome with proteinuria, variable serum creatinine elevation, and sometimes microangiopathic hemolytic features; renal biopsy in such cases may show TMA, FSGS, or a hyaline occlusive glomerular microangiopathy pattern. Serum creatinine is often normal or only mildly elevated even with heavy proteinuria.
Anticancer mechanism
Axitinib is an oral, potent, selective second-generation small-molecule tyrosine kinase inhibitor that blocks vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, and VEGFR-3 at subnanomolar concentrations. By interrupting VEGF-driven angiogenic signaling, it starves the tumor of neovascularization. Its high selectivity for the VEGFR family (relative to first-generation multi-kinase inhibitors) underlies both its antitumor potency and a renal/vascular toxicity profile dominated by on-target VEGF-pathway effects.
Management
Hypertension is managed with standard antihypertensive therapy (ACE inhibitors or ARBs are often favored, partly for antiproteinuric benefit), alongside axitinib dose interruption or reduction for grade 3 or persistent hypertension; in AXIS, hypertension led to dose interruption in 12.8%, dose reduction in 4.5%, and discontinuation in only 0.3%, and roughly half of patients with grade 3-4 hypertension continued treatment for 9 months or more. For significant or nephrotic-range proteinuria, hold or reduce the drug, add/optimize RAAS blockade, and refer to nephrology; proteinuria often improves but may persist after discontinuation. Suspected thrombotic microangiopathy or biopsy-proven severe glomerular injury generally warrants stopping the VEGF inhibitor; withdrawal frequently leads to improvement, and a short corticosteroid course has been used in selected biopsy-proven glomerular cases.Lesion-level management framework
Risk factors
- Pre-existing or poorly controlled hypertension
- Higher axitinib exposure / dose titration (effects are dose-related)
- Pre-existing chronic kidney disease or proteinuria
- Concurrent or sequential use of other VEGF-pathway inhibitors
- Underlying renal cell carcinoma with a single/remnant kidney after nephrectomy
Prevention
- Measure and optimize blood pressure before starting and control pre-existing hypertension
- Obtain baseline and periodic urine protein (dipstick or urine protein-to-creatinine ratio) and serum creatinine
- Use guideline-based blood-pressure monitoring with prompt initiation/titration of antihypertensives (ACE inhibitors/ARBs are commonly preferred, also for their antiproteinuric effect)
- Follow protocol dose-titration rules that withhold dose escalation in patients with uncontrolled hypertension
Note · Renal-focused educational summary; not medical advice. Citations verified via PubMed.
Clinical depth
Renal dose adjustment
No renal dose adjustment is generally required across the range of baseline renal function studied, and patients with mild-to-severe renal impairment have been treated, though data in end-stage renal disease are very limited. Less than 1% of an administered dose is excreted unchanged in urine (axitinib is cleared primarily by hepatic CYP3A4/1A2 metabolism), so renal clearance is not a major elimination route. Dose modification in practice is driven by toxicity (e.g., uncontrolled hypertension, proteinuria) rather than by creatinine clearance, using protocol-based interruptions and reductions.
Dialyzability & ESKD dosing
Not well characterized. Axitinib is a small-molecule, highly protein-bound (>99%) oral TKI with predominantly hepatic clearance and minimal (<1%) urinary excretion of unchanged drug, so meaningful removal by hemodialysis is considered unlikely; specific dialysis-removal data are lacking.
Differential diagnosis
Distinguish VEGF-inhibitor hypertension/proteinuria (on-target, dose-related, often reversible) from pre-existing essential hypertension and diabetic or hypertensive nephropathy. In a patient with heavy proteinuria, declining filtration, or hematologic changes, consider drug-induced thrombotic microangiopathy versus other glomerular lesions (FSGS, minimal-change-like podocytopathy, hyaline occlusive glomerular microangiopathy) — biopsy distinguishes these. When axitinib is combined with an immune checkpoint inhibitor (e.g., pembrolizumab), also consider checkpoint-inhibitor acute interstitial nephritis or ICI-associated podocytopathy as an alternative or contributing cause of renal injury.
Monitoring
- Blood pressure at baseline and frequently during the first weeks, then regularly (home monitoring is useful)
- Urine protein at baseline and periodically (dipstick or urine protein-to-creatinine ratio); quantify if positive
- Serum creatinine / eGFR periodically
- CBC with smear and LDH/haptoglobin if thrombotic microangiopathy is suspected (anemia, thrombocytopenia, schistocytes)
Key trials & series
- AXIS (Rini et al., Lancet 2011): randomized phase III of axitinib vs sorafenib as second-line therapy in metastatic RCC; longer PFS with axitinib (6.7 vs 4.7 months); hypertension among the most common adverse events
- AXIS hypertension analysis (Rini et al., Target Oncol 2014): all-causality hypertension 40.4% with axitinib vs 29.0% with sorafenib; grade 3 in 15.3%; rarely led to discontinuation or cardiovascular sequelae
Clinical pearls
- Hypertension is the headline renal-vascular toxicity and is more frequent with axitinib than with sorafenib (AXIS: 40.4% vs 29.0%).
- Treatment-emergent hypertension/elevated diastolic BP has been explored as a potential pharmacodynamic biomarker of axitinib efficacy, but this remains investigational.
- Heavy proteinuria can occur with a near-normal serum creatinine — monitor urine protein, not just creatinine.
- Proteinuria and hypertension are class effects of VEGF-pathway blockade (shared with bevacizumab, sunitinib, sorafenib, pazopanib) driven by podocyte/glomerular-endothelial VEGF deprivation.
- In axitinib + checkpoint-inhibitor regimens, new kidney injury has a broader differential that includes immune-mediated interstitial nephritis and podocytopathy.
Beyond the kidney — non-renal toxicities· 4 organ systems
Class-level context for the major non-renal toxicities of vegfr tkis.
Vascular
Hypertension, VTE/ATE, bleeding, aneurysm
- Hypertension, arterial/venous thrombosis, bleeding, impaired wound healing
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
- LV dysfunction; QT (some TKIs)
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
- Diarrhea, perforation/fistula
Dermatologic
Rash, HFS, SJS/TEN, vitiligo
- Hand-foot skin reaction
Evidence
7 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkComparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.Rini BI, Escudier B, Tomczak P, et al. · Lancet 2011 · PMID 22056247Pivotal phase III AXIS trial establishing axitinib in second-line metastatic RCC; hypertension among the most common adverse events.PMIDHypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial.Rini BI, Quinn DI, Baum M, et al. · Targeted Oncology 2014 · PMID 24595903Quantifies axitinib hypertension incidence (40.4% all-grade, 15.3% grade 3) and management/discontinuation outcomes — source of the headline incidence figure.PMIDAnalysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma.Lee N, Lee JL, Lee JY. · Targeted Oncology 2023 · PMID 36826462Real-world cohort (n=988) confirming hypertension and proteinuria as the leading anti-angiogenesis-related adverse events across VEGFR-TKIs including axitinib.PMIDVEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management.Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC. · European Journal of Cancer 2009 · PMID 20006922Mechanistic review (explicitly including axitinib) of nephrin suppression, proteinuria incidence (21-63% mild; up to 6.5% heavy), glomerular TMA, and ACEi/ARB-based management.PMIDKidney injury during VEGF inhibitor therapy.den Deurwaarder ESG, Desar IME, Steenbergen EJ, Mulders PF, Wetzels JFM, van Herpen CML. · Netherlands Journal of Medicine 2012 · PMID 22859418Reviews the spectrum of VEGF-inhibitor renal injury — TMA in the majority of biopsies, plus FSGS and interstitial nephritis — informing the glomerular/TMA signature.PMIDVEGF-VEGFR2 inhibitor-associated hyaline occlusive glomerular microangiopathy: a Japanese single-center experience.Ozawa M, Ohtani H, Komatsuda A, Wakui H, Takahashi N. · Clinical and Experimental Nephrology 2021 · PMID 34115234Biopsy series characterizing a distinct glomerular microangiopathy pattern in proteinuric patients on VEGF-VEGFR2 inhibitors, with proteinuria improving after withdrawal.PMIDDrug-Induced Podocytopathies: Report of Four Cases and Review of the Literature.Athanasopoulou D, Lionaki S, Skalioti C, Liapis G, Vlachoyiannopoulos P, Boletis I. · Life (Basel) 2023 · PMID 37374047Reviews drug-induced podocytopathy/nephrotic syndrome including pembrolizumab-axitinib, supporting the glomerular differential in combination regimens.
Guidelines & consensus· 16
KDIGOManagement of Blood Pressure in Patients With Chronic Kidney Disease Not Receiving Dialysis: Synopsis of the 2021 KDIGO Clinical Practice GuidelineAnn Intern Med 2021 · PMID 34152826Recommends standardized office BP measurement and a target systolic BP <120 mm Hg for most CKD patients, with RAAS inhibitors first-line when albuminuria is present — the BP-management basis for anti-VEGF/TKI-induced hypertension and proteinuria.ESC2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)Eur Heart J 2022 · PMID 36017568For VEGF/VEGFR inhibitors, perform baseline cardiovascular risk assessment, monitor blood pressure (weekly during the first cycle, then regularly) and treat to a target <140/90 mmHg with ACE inhibitors/ARBs and dihydropyridine calcium-channel blockers; manage VEGFi-associated hypertension and proteinuria with interruption/dose modification when severe.ESCEuropean Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatmentEur Heart J Qual Care Clin Outcomes 2022 · PMID 36316010Adherence quality indicators require documented baseline cardiovascular risk assessment and structured monitoring of cardiovascular complications (including hypertension) during cancer therapy such as VEGF-pathway inhibitors.UK expert oncology/cardiology consensus panelUsing bevacizumab to treat metastatic cancer: UK consensus guidelinesBr J Hosp Med (Lond) 2010 · PMID 21135762Assess and monitor blood pressure and proteinuria during bevacizumab therapy; treat emergent hypertension to standard targets and interrupt/discontinue the drug for uncontrolled hypertension, nephrotic-range proteinuria or other severe vascular toxicity.
General onco-nephrology references
Acute Disease Quality InitiativeThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.Cancer Institute NSWIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.Cancer Institute NSWAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.Cancer Institute NSWA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.